We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Simple Genetic Test Identifies Susceptibility for Prostate Cancer

By Labmedica staff writers
Posted on 28 Jan 2008
Men with susceptibility for prostate cancer will soon be identifiable through a simple DNA test. More...


At present, men suspected of suffering from prostate cancer are identified mainly using the prostate-specific antigen (PSA) tests. PSA is a substance secreted by epithelial cells in the prostate. However, the PSA test has a relatively low sensitivity and more effective methods are required.

Prostate cancer is partly caused by inherited factors making some men more likely to develop the disease. From the five relatively common gene variants identified that affect this risk, each affects the risk only marginally, and they have been of no real benefit to individual patients.

Scientists at the Swedish medical university, Karolinska Institutet (Stockholm, Sweden), have shown that men carrying a combination of known risk genes run a four to five times higher risk of developing prostate cancer. Together with American colleagues these scientists have analyzed the cumulative effect of these gene variants for the first time. The results showed that men who carry four or more risk variants have a four to five times greater risk of developing prostate cancer. This risk is increased even more if they also had close relatives with the disease.

Published online in The New England Journal of Medicine (NEJM) on January 16, 2008, the study was based on genetic analyses of approximately 4,800 Swedish men, of whom 3,000 had prostate cancer and 1,800 had no prostate cancer diagnosis.

"In the near future, it will be possible to combine PSA tests with simple genetic tests,” said Professor Henrik Grönberg at the Karolinska Institutet. "This means that fewer men will have to undergo unnecessary biopsies and that more prostate cancer diagnoses can be made.”


Related Links:
Karolinska Institutet

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.